Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001012 | 1.00 | POLB (0.40) | POLBNOTUMMAPTMEN1KMT2A | |
| SCHEMBL19001045 | 0.83 | MAPT (0.42) | NOTUMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL19012613 | 0.83 | MAPT (0.42) | NOTUMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL19001258 | 0.83 | MAPT (0.38) | POLBMAPTMEN1KMT2ANPC1 | |
| SCHEMBL19001020 | 0.83 | MAPT (0.38) | POLBMAPTMEN1KMT2ANPC1 | |
| SCHEMBL19001249 | 0.81 | MAPT (0.38) | POLBNOTUMMAPTMEN1KMT2A | |
| SCHEMBL19000982 | 0.81 | MAPT (0.38) | POLBNOTUMMAPTMEN1KMT2A | |
| SCHEMBL13727502 | 0.77 | MAPT (0.45) | NOTUMMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL21718936 | 0.76 | MEN1 (0.47) | POLBNOTUMMAPTMEN1KMT2A | |
| SCHEMBL16001193 | 0.74 | HTR3A (0.47) | MAPTMEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | POLB 4131/4885NOTUM 4058/4885MAPT 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.